Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum Pfs230 is a large, 230 kDa surface protein expressed during the sexual stages of the malaria parasite's life cycle. It is a member of the 6-Cys protein family and is localized to the surface of gametocytes and gametes. Pfs230 is essential for the fertilization of gametes within the mosquito midgut, where it facilitates the transition from gametes to zygotes and subsequently to ookinetes. Because it is exposed to the host immune system and critical for transmission, it is a leading candidate for transmission-blocking vaccines (TBVs). These vaccines work by inducing antibodies in humans that, when ingested by a mosquito during a blood meal, interfere with the parasite's development, thereby preventing the mosquito from becoming infectious. Clinical development often utilizes the first domain (D1) of the protein, frequently conjugated to carrier proteins to improve the immune response.
Induction of transmission-blocking antibodies that bind to the gamete surface, preventing fertilization and subsequent development into ookinetes in the mosquito midgut.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum gametocyte surface protein Pfs230 (Pfs230).